Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

NICE technology appraisals [TA192] Published date:

NICE recommends gefitinib as a possible first treatment for some people with locally advanced or metastatic non-small-cell lung cancer (see below).
Who can have gefitinib?

You should be able to have gefitinib if:

  • you have a type of locally advanced or metastatic non-small-cell lung cancer that responds to gefitinib treatment and
  • you have not had drug treatment for non-small-cell lung cancer before.

Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended gefitinib because it is a new type of treatment for locally advanced or metastatic non-small-cell lung cancer which works as well as other treatments available on the NHS and costs about the same.

Get involved